NCT02467920View on ClinicalTrials.gov

Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

PHASE4CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

glargine + exenatide

glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)

DRUG

aspart 30

aspart 30 ( subcutaneous injection, twice daily)

Trial Locations (1)

430000

Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology, Wuhan

All Listed Sponsors
lead

Huazhong University of Science and Technology

OTHER

NCT02467920 - Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM | Biotech Hunter | Biotech Hunter